Company profile: Rubius Therapeutics
1.1 - Company Overview
Company description
- Provider of technology to grow, genetically engineer, and mature long-circulating Red-Cell Therapeutics.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Rubius Therapeutics
Chromatin
HQ: United States
Website
- Description: Provider of plant breeding and genomics technologies for agricultural, energy, chemical, nutritional and pharmaceutical sectors. Develops sorghum for agriculture and renewable energy, and advances maize and wheat via high-yielding, disease- and climate-resilient traits. Services include genomic selection, high-throughput phenotyping, multi-trait analysis, environics for genotype prediction, and integrated genomics-phenomics modeling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chromatin company profile →
BioFluidica
HQ: United States
Website
- Description: Provider of a biotechnology diagnostic platform and automated liquid biopsy microfluidic system to isolate and enrich rare biomarkers—circulating tumor cells, exosomes, and trophoblasts—from body fluids; offers exosome and CTC isolation for research and cbNIPT, plus the B³ Blood Collection Tube for room-temperature whole blood shipping with buffer to inhibit micro-clotting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioFluidica company profile →
Eligo Bioscience
HQ: France
Website
- Description: Provider of CRISPR/Cas and engineered phage capsid-based antimicrobials and microbiome editing technologies to control bacterial ecosystems in humans and animals. Solutions include the GEM platform for in vivo gene editing, SSAM sequence-specific antimicrobials, FAME for therapeutic gene addition, and capabilities for gene removal, modification, and addition to eradicate resistant pathogens and modulate disease mechanisms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eligo Bioscience company profile →
Vigene Biosciences
HQ: United States
Website
- Description: Provider of gene delivery technologies and cell and gene therapy CDMO solutions, offering research- and cGMP-grade AAV, lentivirus, and adenovirus products and custom services, including ready-to-ship genome-wide human cDNA ORFs on adenoviral or lentiviral, supporting therapy development and production to advance biomedical research and make gene therapy affordable.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vigene Biosciences company profile →
CTI BioPharma
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology products for cancer treatment, focused on blood-related cancers. Develops, acquires, and commercializes therapies including Pixantrone (Phase III; non-Hodgkin's lymphoma), Brostallicin (first-line Phase II; sarcoma), and OPAXIO chemotherapeutic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CTI BioPharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Rubius Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Rubius Therapeutics
2.2 - Growth funds investing in similar companies to Rubius Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Rubius Therapeutics
4.2 - Public trading comparable groups for Rubius Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →